[City, October 15, 2026]: Mankind Pharma has signed a definitive agreement to acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million, marking its entry into the next-generation CAR-T therapy segment for cancer.
The acquisition is aimed at expanding Mankind Pharma’s presence in advanced cancer therapies, the company said. Armed Cell Therapeutics is engaged in developing CAR-T programmes targeting non-Hodgkin lymphoma and small cell lung cancer.
Strategic move into CAR-T therapies
The investment will enable Mankind Pharma to access innovative cell therapy technologies and strengthen its oncology portfolio with a focus on cutting-edge treatments for cancer patients.
Focus on non-Hodgkin lymphoma and lung cancer
Armed Cell Therapeutics is currently working on CAR-T therapy programmes specifically targeting non-Hodgkin lymphoma and small cell lung cancer, which are areas of significant unmet medical need.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
